Translucence Biosystems’ Post

Translucence Biosystems is gearing up for #AAIC2024 in Philadelphia on July 28 – Aug. 1. Our Co-Founder & CEO, Damian Wheeler, PhD, and expert Chase Redd will be presenting tools, technologies, and #3Dhistology techniques that are furthering Alzheimer's research. We're showcasing two posters: • “Brain-Wide Cellular-Resolution Measurement of Antibody Therapeutic Biodistribution” • “Brain-Wide Cellular-Resolution Quantification of Amyloid Plaques and Microglia in AD Model Mice” These posters highlight how tissue clearing and lightsheet microscopy methods enable unbiased, brain-wide analysis of therapeutics and neuroinflammation, offering cellular resolution measurements of BBB penetration of antibody therapeutics and providing AI-powered quantification of #amyloidplaques and #microglia across entire mouse brains. Join us at #AAIC2024 to learn more about how #tissueclearing and #lightsheet #microscopy advances can accelerate pre-clinical CNS therapeutic development and shape the future of #AlzheimersDisease research. We're looking forward to engaging with fellow researchers and advancing our collective understanding of Alzheimer's disease. #Neuroscience, #AlzheimersResearch, #Biotech, #Innovation, #CNSDrugDevelopment, Alzheimer's Association®

Our axoCells™ Astrocytes line (ax0704) is designed to fuel robust in vitro models for neurodegenerative disease research and drug discovery. With labs around the world increasingly moving to in vitro models, drug discovery researchers are embracing human iPSC-derived cells to build more human, more functional models for neuroscience. But with many labs still using rat astrocytes for their work (with very long protocols, some even >100 days), we're "supporting the switch" to human iPSCs with our axoCells Astrocytes product that can drive faster, cheaper in vitro workflows. Key highlights of our axoCells Astrocytes product include: • Best price on the market • Derived from fibroblasts taken from a healthy 40-50-year-old male donor • Assay ready in just 48 hours • Express seven key markers of primary human astrocytes including GFAP, AQP4 and S100B and astrocyte-associated markers (EAAT1 and ALDH1L1) with low levels of neuronal progenitor markers including Nestin • Specifically developed for use in powerful in vitro monoculture models and complex co-culture systems for drug discovery Click here to read more about this product line and how you can use axoCells Astrocytes to power robust, physiologically relevant models of Alzheimer’s Disease, Parkinson’s Disease and ALS: https://hubs.la/Q02H3-SF0 Want to explore the details and get a quote? Click here: https://hubs.la/Q02H3Rb_0 #iPSCs #Astrocytes #AlzheimersDisease #ParkinsonsDisease #ALS #DrugDiscovery

Our axoCells™ Astrocytes line (ax0704) is designed to fuel robust in vitro models for neurodegenerative disease research and drug discovery. With labs around the world increasingly moving to in vitro models, drug discovery researchers are embracing human iPSC-derived cells to build more human, more functional models for neuroscience. But with many labs still using rat astrocytes for their work (with very long protocols, some even >100 days), we're "supporting the switch" to human iPSCs with our axoCells Astrocytes product that can drive faster, cheaper in vitro workflows. Key highlights of our axoCells Astrocytes product include: • Best price on the market • Derived from fibroblasts taken from a healthy 40-50-year-old male donor • Assay ready in just 48 hours • Express seven key markers of primary human astrocytes including GFAP, AQP4 and S100B and astrocyte-associated markers (EAAT1 and ALDH1L1) with low levels of neuronal progenitor markers including Nestin • Specifically developed for use in powerful in vitro monoculture models and complex co-culture systems for drug discovery Click here to read more about this product line and how you can use axoCells Astrocytes to power robust, physiologically relevant models of Alzheimer’s Disease, Parkinson’s Disease and ALS: https://hubs.la/Q02H3DrG0 Want to explore the details and get a quote? Click here: https://hubs.la/Q02H44NX0 #iPSCs #Astrocytes #AlzheimersDisease #ParkinsonsDisease #ALS #DrugDiscovery

Join host Jo Anne Stratton for the next Killam Seminar Series, given by Iain Clark, Assistant Professor of Bioengineering at University of California, Berkeley. His lab recently developed two novel approaches to study astrocyte-microglia interactions at the single-cell level during inflammation: 1) an in vivo barcoding-based strategy that analyzes the transcriptomes and connections between individual cells, and 2) a droplet-based platform for genome-wide, unbiased CRISPR/Cas9 screening of genes that mediate cell crosstalk. In this seminar, he will discuss the development of these technologies and their application to study astrocyte-microglia signaling in experimental autoimmune encephalomyelitis (EAE), a preclinical mouse model of MS. 📅 Feb. 20 from 4-5 p.m. https://lnkd.in/ewhGiGat #neuroscience #MS #multiplesclerosis #bioengineering

Watch the full feature https://lnkd.in/e7KfQg6e

📢 Breakthrough Alzheimer’s News in #NEJM: Focused Ultrasound Combined with Antibody Treatment May Slow Disease Progression The prestigious New England Journal of Medicine published promising results today from a first-in-human study showing combination #focusedultrasound treatment can accelerate the clearance of plaques in the brains of Alzheimer’s patients. Researchers at WVU Rockefeller Neuroscience Institute used INSIGHTEC’s focused ultrasound device in combination with monoclonal antibody treatment to safely and temporarily open the blood-brain barrier to allow anti-amyloid-beta antibodies increased access to targeted areas of the brain – increasing amyloid-beta plaque reduction by an average of 32% over six months. “This is a highly important milestone in the development of focused ultrasound for treating Alzheimer's disease by enhancing the safety and efficacy of drug delivery,” said Foundation Chairman Neal F. Kassell, MD. “The study builds on a growing body of preclinical laboratory studies and clinical trials, much of which were funded by the Foundation, and we look forward to additional research that will lead to slowing the disease progression and improving cognition in patients with Alzheimer's disease.” Read more about this groundbreaking #AlzheimersResearch: https://ow.ly/qwat50QnZSE #Neuroscience #MedicalResearch

Our new neuroscience brochure is now available for you to download for insight into: 💡Panel of models with increasing complexity and translational relevance: • Cell lines for central and peripheral nervous system targets. • Primary neuronal cultures, such as dissociated cortical, trigeminal or DRG. • CNS drug discovery to understand the effects of test compounds on brain slice tissue. • Human iPSC-derived neurons. 💡Range of assay methodologies to help you investigate the mechanism of action for pre-clinical compounds, confirm compound effects, address the neurotoxicity of compounds and assess the effects of compounds on a range of excitability parameters: • Heterologous cell lines and integrative assays. • Selectivity and safety profiling of lead compounds and IND candidates. • Translational assays: central and peripheral neuronal firing, and native ion channel screening assays. 💡Studying ion channels on the lysosomal membrane. 💡CNS drug discovery to understand the effects of test compounds on brain slice tissue. 📄Case study: Multi-assay high-throughput repurposing screen for rare epilepsy mutation in KCNC1 gene. As a specialist preclinical drug discovery CRO, we pride ourselves on delivering high quality data, on time and on budget. Find out more about our neuroscience services and download the brochure: https://hubs.la/Q02GXJCC0 Contact us to request a meeting or quote: https://hubs.la/Q02GXhnX0 #neuroscience #drugdiscovery #cro #ionchannels #lifesciences #cns #electrophysiology

🌟 𝐈𝐧𝐌𝐞𝐝'𝐬 𝐈𝐍𝐌-𝟗𝟎𝟏: 𝐀 𝐍𝐞𝐰 𝐇𝐨𝐩𝐞 𝐟𝐨𝐫 𝐀𝐥𝐳𝐡𝐞𝐢𝐦𝐞𝐫’𝐬 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭! 💡 𝗜𝗻 𝗝𝘂𝗹𝘆 𝟮𝟬𝟮𝟰, InMed Pharmaceuticals recently released preclinical data indicating its proprietary, #smallmolecule compound, INM-901, targets multiple #biological pathways associated with #Alzheimer’sdisease. Among the most interesting data from the recent reports, was the ability of its compound to extend the length of #neurites, which may indicate enhanced neuronal functioning in the #brain and the potential to reverse the #damage caused by Alzheimer’s disease. The company was encouraged with these breakthrough preclinical results and will be advancing the development of the INM-901 Alzheimer’s disease program. InMed's preclinical model of Alzheimer's disease, which is well characterised, showed encouraging outcomes in both in vitro and in vivo trials. The study claims that it might encourage neurite growth and extension, or neutogenesis, a crucial aspect of cell-to-cell communication. In in-vivo experiments, INM-901 also revealed decreased neuroinflammation and improved behaviour, memory, and cognitive function. 𝗕𝗿𝗼𝘄𝘀𝗲 𝗮𝘁 𝗼𝘂𝗿 𝗥𝗲𝗹𝗮𝘁𝗲𝗱 𝗥𝗲𝗽𝗼𝗿𝘁 👉:https://bit.ly/46jbV2x #AlzheimersTreatment #InnovativeTherapy #AlzheimersResearch #MultiFactorialApproach #BreakthroughMedicine #NeuroScience #AlzheimersHope #prophecymarketinsights

Delve deeper into groundbreaking research from LKCMedicine, led by Assistant Professors Xia Yun and Jia Nee Foo, along with the dedicated research team including Research Associate Liu Meng and Research Fellow Dr Zhang Chao. Shedding light on potential breakthrough therapies for Polycystic Kidney Disease (PKD), the study cultivates 'mini kidneys' in the lab and implants them into live mice, uncovering crucial insights into PKD's metabolic dysfunctions. Explore the published study in Cell Stem Cell to learn more about the innovative approach and its implications for advancing PKD treatment. Read more: https://lnkd.in/gkhkPDxa #ResearchInnovation #LKCMedicine #PKDResearch